Search results for "medicine.drug_class"

showing 10 items of 2726 documents

Enzephalopathie nach Intoxikation mit einem Anticholinergikum

2008

A 55-year-old chemical laboratory technician developed mydriasis and ocular hypertension, which lasted for 6 weeks, after synthesizing several kilograms of a scopolamine-related test agent with anticholinergic action and then decanting a powdery intermediary substance, the dust of which he may have inhaled. Six weeks later he suddenly had symptoms of an acute intoxication while synthesizing a scopolamine-related substance. The anticholinergic delirium regressed completely within one day requiring no treatment. But subsequently he developed symptoms of a toxic encephalopathy. This only partially regressed over the following 3 years. Its probable cause is thought to have been either the manif…

medicine.drug_classbusiness.industryToxic encephalopathyAcute intoxicationOcular hypertensionGeneral MedicineChemical laboratoryTest agentmedicine.diseaseAnesthesiamedicineAnticholinergicMydriasisDeliriummedicine.symptombusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Paroxetine Administration Affects Microbiota and Bile Acid Levels in Mice.

2020

Recent interest in the role of microbiota in health and disease has implicated gut microbiota dysbiosis in psychiatric disorders including major depressive disorder. Several antidepressant drugs that belong to the class of selective serotonin reuptake inhibitors have been found to display antimicrobial activities. In fact, one of the first antidepressants discovered serendipitously in the 1950s, the monoamine-oxidase inhibitor Iproniazid, was a drug used for the treatment of tuberculosis. In the current study we chronically treated DBA/2J mice for 2 weeks with paroxetine, a selective serotonin reuptake inhibitor, and collected fecal pellets as a proxy for the gut microbiota from the animals…

medicine.drug_classlcsh:RC435-571Serotonin reuptake inhibitorClinical SciencesmicrobiomeGut floraPharmacology03 medical and health sciences0302 clinical medicineRare Diseaseslcsh:PsychiatrymedicinePsychologyMicrobiomeCancerOriginal ResearchPsychiatrybile acidsantidepressantbiologyBile acidbusiness.industryDepressionbiology.organism_classificationmedicine.diseaseParoxetinemetabolomics030227 psychiatryColo-Rectal CancerPsychiatry and Mental healthMental HealthGood Health and Well Being5.1 PharmaceuticalsPublic Health and Health ServicesAntidepressantDevelopment of treatments and therapeutic interventionsbusinessDigestive DiseasesDysbiosis030217 neurology & neurosurgeryBehavioural despair testmedicine.drugparoxetineFrontiers in psychiatry
researchProduct

Modulation of melanoma-associated antigens by monoclonal antibodies as visualized by radioimmunoelectron microscopy and radioantibody binding assay

1987

There is a wealth of information about monoclonal antibody (MAb) specificity and function on fixed tissues, yet little is known about formation and release of antigen-antibody complexes and their functional behavior in vivo. We analyzed the pathway of radiolabeled MAbs directed against melanoma-associated antigens by radioimmunoelectron microscopy (RIEM) on metabolically active cells of the melanoma cell lines SK-MEL-28, MeWo and Colo 38 at different time intervals. In parallel, binding and release of MAbs were investigated by the radioantibody binding assay (RBA). Both procedures gave essentially concordant results. Preferentially stable binding of immune complexes (ICs) to the cell surfac…

medicine.drug_classmedia_common.quotation_subjectMelanoma ExperimentalRadioimmunoassayCoated vesicleAntigen-Antibody ComplexDermatologyBiologyEndocytosisMonoclonal antibodyCell LineCell membranemedicineInternalizationmedia_commonLigand binding assayAntibodies MonoclonalGeneral MedicineVirologyMolecular biologyEndocytosisMicroscopy Electronmedicine.anatomical_structureCytoplasmAutoradiographyAntigenic ModulationBinding Sites AntibodyArchives of Dermatological Research
researchProduct

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct

Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.

2013

The T-helper epitope peptide P30 (green in the scheme) from tetanus toxoid was used as the immunostimulant in MUC1 glycopeptide antitumor vaccines and apparently also acts as a built-in adjuvant. P30-conjugated glycopeptide vaccines containing three glycans in the immunodominant motifs PDTRP and GSTAP induced much stronger immune responses and complement dependent cytotoxicity mediated killing of tumor cells when applied in plain PBS solution without complete Freund's adjuvant.

medicine.drug_classmedicine.medical_treatmentEpitopes T-Lymphocytecomplex mixturesImmunostimulantCancer VaccinesCatalysisEpitopeEpitopesImmune systemmedicineTetanus ToxoidHumansTetanusChemistryMucin-1ToxoidGlycopeptidesGeneral Chemistrymedicine.diseaseVirologyComplement-dependent cytotoxicityGlycopeptideEpitopes B-LymphocytePeptidesAdjuvantAngewandte Chemie (International ed. in English)
researchProduct

Interleukin-15, as Interferon-gamma, Induces the Killing of Leishmania infantum in Phorbol-Myristate-Acetate-Activated Macrophages Increasing Interle…

2004

The potential leishmanicidal activity of interleukin-15 (IL-15) was examined while priming with the cytokine phorbol-myristate-acetate (PMA)-activated macrophages and infecting them with Leishmania infantum parasites. The activation of macrophage cultures with IL-15 determined a significant anti-leishmanial activity, comparable with that induced by interferon-gamma (IFN-gamma). The killing of Leishmania in macrophages primed with IL-15, as well as with IFN-gamma, was followed by an increase in the IL-12 synthesis. The neutralization of IL-15 or IFN-gamma, by specific monoclonal antibodies (MoAb) caused a significant reduction in leishmanicidal activity. Furthermore, in PMA-activated macroph…

medicine.drug_classmedicine.medical_treatmentImmunologyMonoclonal antibodyNeutralizationMicrobiologyInterferon-gammaMicemedicineAnimalsInterferon gammaLeishmania infantumInterleukin-15biologyActivator (genetics)MacrophagesGeneral Medicinebiology.organism_classificationInterleukin-12CytokineInterleukin 15Interleukin 12Leishmaniasis VisceralTetradecanoylphorbol AcetateLeishmania infantummedicine.drugScandinavian Journal of Immunology
researchProduct

Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy

2003

Renal cell carcinoma (RCC) represents the most common malignant tumor in the kidney and is resistant to conventional therapies. The diagnosis of RCC is often delayed leading to progression and metastatic spread of the disease. Thus, validated markers for the early detection of the disease as well as selection of patients undergoing specific therapy is urgently needed. Using treatment with the monoclonal antibody (mAb) G250 as a model, proteome-based strategies were implemented for the identification of markers which may allow the discrimination between responders and nonresponders prior to application of G250-mediated immunotherapy. Flow cytometry revealed G250 surface expression in approxi…

medicine.drug_classmedicine.medical_treatmentMonoclonal antibodyBiochemistryMass SpectrometryFlow cytometrySequence Analysis ProteinRenal cell carcinomaCell Line TumorBiomarkers TumormedicineCarcinomaHumansElectrophoresis Gel Two-DimensionalCarcinoma Renal CellMolecular Biologybiologymedicine.diagnostic_testAntibodies MonoclonalProteinsImmunotherapyFlow Cytometrymedicine.diseaseKidney NeoplasmsImmunologyProteomebiology.proteinCancer researchImmunohistochemistryImmunotherapyAntibodyPROTEOMICS
researchProduct

Injection of Donor-Derived OX62+ Splenic Dendritic Cells With Anti-CD4 Monoclonal Antibody Generates CD4+CD25+FOXP3+ Regulatory T Cells That Prolong …

2009

Abstract Objective To examine in a rat model the ability of donor dendritic cells and anti-CD4 monoclonal antibody (mAb) to generate donor-specific CD4+CD25+ regulatory T cells (Tregs) and to evaluate the capacity of these Tregs to prolong skin allograft survival and abrogate the production of donor-specific antibodies after skin grafting. Materials and Methods OX62+ (nonplasmacytoid) splenic dendritic cells were isolated from Fischer rats using magnetic beads and injected (2 × 10 6 ) into Lewis rat recipients with or without treatment with a nondepleting anti-CD4 (W3/25) mAb. After 4 weeks, splenic CD4+CD25+FOXP3+ T cells were harvested using magnetic beads from conditioned animals and inj…

medicine.drug_classmedicine.medical_treatmentSpleenMonoclonal antibodyT-Lymphocytes RegulatoryIsoantibodiesRats Inbred BNAnimalsTransplantation HomologousMedicineIL-2 receptorAntigen-presenting cellTransplantationbusiness.industryGraft SurvivalInterleukin-2 Receptor alpha SubunitAntibodies MonoclonalForkhead Transcription FactorsDendritic CellsSkin TransplantationDendritic cellDonor LymphocytesRats Inbred F344RatsTransplantationmedicine.anatomical_structureRats Inbred LewCD4 AntigensModels AnimalImmunologySkin graftingSurgerybusinessTransplantation Proceedings
researchProduct

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study

2021

AIMS: Although acute heart failure (AHF) with volume overload is treated with loop diuretics, their dosing and type of administration are mainly based upon expert opinion. A recent position paper from the Heart Failure Association (HFA) proposed a step-wise pharmacologic diuretic strategy to increase the diuretic response and to achieve rapid decongestion. However, no study has evaluated this protocol prospectively. METHODS AND RESULTS: The Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure (ENACT-HF) study is an international, multicentre, non-randomized, open-label, pragmatic study in AHF patients on chronic loop diuretic therapy, admitted to the hospital for intravenous …

medicine.drug_classmedicine.medical_treatmentStudy DesignsDecongestionVolume overloadDiuresisNatriuresisSodium Potassium Chloride Symporter InhibitorsFurosemideAcute heart failure; Diuretics; Urinary sodium; Decongestion; ProtocolmedicineClinical endpointProtocolHumansDiseases of the circulatory (Cardiovascular) systemInfusions IntravenousDiureticsHeart FailureUrinary sodiumStudy Designbusiness.industryFurosemideAcute heart failureLoop diureticmedicine.diseaseAnesthesiaHeart failureRC666-701DiureticCardiology and Cardiovascular Medicinebusinessmedicine.drugESC Heart Failure
researchProduct

BCR-ABL as a target for novel therapeutic interventions.

2002

The BCR-ABL oncogene is the result of a reciprocal translocation between the long arms of chromosome 9 and 22 t(9; 22). There is good experimental evidence demonstrating that BCR-ABL is the single causative abnormality in chronic myeloid leukaemia (CML), making it a unique model for the development of molecular targets. In addition to CML, BCR-ABL transcripts can be found in a minority of acute lymphoblastic leukaemias and very rarely in acute myeloid leukaemia (AML). Elucidating the molecular mechanisms and downstream pathways of BCR-ABL has led to the design of several novel therapeutic approaches. In this review, molecular targeting of BCR-ABL will be discussed based on the inhibition of…

medicine.drug_classmedicine.medical_treatmentT-LymphocytesClinical BiochemistryFusion Proteins bcr-ablChromosomal translocationChromosome 9Antineoplastic AgentsBiologyGenes ablTyrosine-kinase inhibitorhemic and lymphatic diseasesNeoplasmsDrug DiscoverymedicineAnimalsHumansneoplasmsGenePharmacologyOncogeneImmunotherapyProtein-Tyrosine KinasesFusion proteinCell Transformation NeoplasticImmunologyMolecular MedicineSignal transductionSignal TransductionExpert opinion on therapeutic targets
researchProduct